Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4⁺ T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation.

ABSTRACT: Post-transplantation cyclophosphamide (PTCy) reduces the incidence and severity of graft-versus-host disease (GVHD), thereby improving the safety and accessibility of allogeneic hematopoietic cell transplantation (HCT). We have shown that PTCy works by inducing functional impairment and suppression of alloreactive T cells. We also have identified that reduced proliferation of alloreactive CD4⁺ T cells at day +7 and preferential recovery of CD4⁺CD25⁺Foxp3⁺ regulatory T cells (T_regs) at day +21 are potential biomarkers associated with optimal PTCy dosing and timing in our B6C3F1→B6D2F1 MHC-haploidentical murine HCT model. To understand whether the effects of PTCy are unique and also to understand better the biology of GVHD prevention by

SUBMITTER: Hadjis AD 

PROVIDER: S-EPMC8886236 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature